Jacob J. Adashek

Follow

Generating author description...

Common Coauthors
Commonly Cited References
Action Title Year Authors # of times referenced
+ PDF Chat Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms 2016 Maria Schwaederlé
Melissa Zhao
J. Jack Lee
Vladimir Lazar
Brian Leyland‐Jones
Richard L. Schilsky
John Mendelsohn
Razelle Kurzrock
2
+ PDF Chat Early phase clinical trials to identify optimal dosing and safety 2014 Natalie Cook
Aaron R. Hansen
Lillian L. Siu
Albiruni R. Abdul Razak
1
+ PDF Chat Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse 2010 Rajul K. Jain
J. Jack Lee
David S. Hong
Maurie Markman
Jing Gong
Aung Naing
Jennifer J. Wheler
Razelle Kurzrock
1
+ Ethical and Design Issues of Phase I Clinical Trials in Cancer Patients 2007 Hans GrĂŒnwald
1
+ Phase I trials in oncology: a new era has started 2014 Sophie Postel‐Vinay
Jean‐Charles Soria
1
+ PDF Chat Optimal two-stage designs for phase II clinical trials 1989 Richard Simon
1
+ Bayesian Model Averaging Continual Reassessment Method for Bivariate Binary Efficacy and Toxicity Outcomes in Phase I Oncology Trials 2014 T. Asakawa
Akihiro Hirakawa
Chikuma Hamada
1
+ Risks and Benefits of Phase 1 Oncology Trials, Revisited 2005 Razelle Kurzrock
Robert S. Benjamin
1
+ Design and Analysis of Phase I Clinical Trials 1989 Barry E. Storer
1
+ PDF Chat Comparison of Outcomes of Phase II Studies and Subsequent Randomized Control Studies Using Identical Chemotherapeutic Regimens 2005 Mohammad I. Zia
Lillian L. Siu
Gregory R. Pond
Eric X. Chen
1
+ Patient-Reported Outcomes in Cancer Drug Development and US Regulatory Review 2015 Ethan Basch
Cindy Geoghegan
Stephen Joel Coons
Ari Gnanasakthy
Ashley F. Slagle
Elektra J. Papadopoulos
Paul G. Kluetz
1
+ PDF Chat Patient-reported Outcomes in Randomised Controlled Trials of Prostate Cancer: Methodological Quality and Impact on Clinical Decision Making 2013 Fabio Efficace
Michael Feuerstein
Peter Fayers
Valentina Cafaro
James A. Eastham
Andrea L. Pusic
Jane Blazeby
1
+ Ethics of Phase 1 Oncology Studies 2003 Manish Agrawal
Ezekiel J. Emanuel
1
+ Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer Drugs 2013 Denis L. Jardim
Kenneth R. Hess
Patricia LoRusso
Razelle Kurzrock
David S. Hong
1
+ PDF Chat Dose Escalation Methods in Phase I Cancer Clinical Trials 2009 Christophe Le Tourneau
J. Jack Lee
Lillian L. Siu
1
+ PDF Chat American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment 2014 Jeffrey S. Weber
Laura A. Levit
Peter C. Adamson
Suanna S. Bruinooge
Howard A. Burris
Michael A. Carducci
Adam P. Dicker
Mithat Gönen
Stephen J. O’Keefe
Michael A. Postow
1
+ Suggestions for the presentation of quality of life data from clinical trials 1998 David Machin
Simon Weeden
1
+ Ultimate Fate of Oncology Drugs Approved by the US Food and Drug Administration Without a Randomized Trial 2009 Apostolia M. Tsimberidou
Fadi Braiteh
David J. Stewart
Razelle Kurzrock
1
+ Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical Trials 2004 Thomas G. Roberts
1
+ PDF Chat Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002 2005 Elizabeth Horstmann
Mary S. McCabe
Louise B. Grochow
Seiichiro Yamamoto
Larry Rubinstein
Troy Budd
Dale Shoemaker
Ezekiel Emanuel
Christine Grady
1
+ PDF Chat Predicting the Outcome of Phase III Trials using Phase II Data: A Case Study of Clinical Trial Simulation in Late Stage Drug Development 2005 Filip De Ridder
1
+ PDF Chat Evolution of Clinical Trial Design in Early Drug Development: Systematic Review of Expansion Cohort Use in Single-Agent Phase I Cancer Trials 2013 Arif Manji
Irene Braña
Eitan Amir
George Tomlinson
Ian F. Tannock
Philippe L. BĂ©dard
Amit M. Oza
Lillian L. Siu
Albiruni R. Abdul Razak
1
+ Responses and toxic deaths in Phase I clinical trials 1990 Genevieve Decoster
Gerburg M. Stein
E. E. Holdener
1
+ PDF Chat Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors 2016 Geoffrey R. Oxnard
Katharine H. Wilcox
Mithat Gönen
Mikhael Polotsky
Bradford R. Hirsch
Lawrence H. Schwartz
1
+ Therapeutic response in phase I trials of antineoplastic agents. 1986 E Estey
Daniel F. Hoth
Ronald Simon
Silvia Marsoni
B Leyland-Jones
R. Wittes
1
+ PDF Chat Is Participation in Cancer Phase I Trials Really Therapeutic? 2016 Jonathan Kimmelman
1
+ Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review 2016 Denis L. Jardim
Eric S. Groves
Philip P. Breitfeld
Razelle Kurzrock
1
+ Precision medicine needs randomized clinical trials 2017 Everardo D. Saad
Xavier PaolettĂ­
Tomasz Burzykowski
Marc Buyse
1
+ PDF Chat Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities 2017 Ricardo Costa
Rubens B. Costa
Sarah Talamantes
Irene Helenoswki
Benedito A. Carneiro
Young Kwang Chae
William J. Gradishar
Razelle Kurzrock
Francis J. Giles
1
+ PDF Chat Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis 2018 Marcin WaligĂłra
MaƂgorzata M BaƂa
Magdalena Koperny
Mateusz T. Wasylewski
Karolina StrzeboƄska
RafaƂ Jaeschke
Agnieszka WoĆșniak
Jan Piasecki
Agnieszka ƚliwka
Jerzy Mituƛ
1
+ Encouraging Trends in Modern Phase 1 Oncology Trials 2018 Camille Chakiba
Thomas Grellety
Carine Bellera
A. Italiano
1
+ US Food and Drug Administration review of statistical analysis of patient-reported outcomes in lung cancer clinical trials approved between January, 2008, and December, 2017 2019 Mallorie H. Fiero
Jessica Roydhouse
Jonathon Vallejo
Bellinda L. King‐Kallimanis
Paul G. Kluetz
Rajeshwari Sridhara
1
+ PDF Chat Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement 2020 Sarah P. Blagden
Lucinda Billingham
Louise Brown
Sean Buckland
Alison M. Cooper
Stephanie Ellis
Wendy Fisher
H Hughes
Debbie Keatley
F. Maignen
1
+ PDF Chat Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards 2022 Edoardo Crimini
Matteo Repetto
Paolo Tarantino
Liliana Ascione
Gabriele Antonarelli
Elena Guerini‐Rocco
Massimo Barberis
Luca Mazzarella
Giuseppe Curigliano
1
+ Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022 2022 Daniel Vilarim AraĂșjo
Alastair Greystoke
SE Bates
A. Bayle
Emiliano Calvo
Luis Castelo‐Branco
Johann S. de Bono
Alexander Drilon
Elena Garralda
Percy Ivy
1
+ PDF Chat What can we do about exploratory analyses in clinical trials? 2015 Lem Moyé
1
+ Patient preferences in the treatment of genitourinary cancers 2023 David J. Benjamin
Arash Rezazadeh Kalebasty
1